CD4 and neoplasm: Most importantly, we revealed that Xevinapant treatment positively reprogramed the immunosuppressive TME in several ways: (i) increasing the immune cells infiltration into the tumor tissue; (ii) increasing CD4 T cells, macrophages, neutrophils and DCs; (iii) inhibiting E2F signaling which is a critical transcription factor that negatively regulates the maturation of DCs; and (iv) positively regulating cytokine production and activating immune response signaling pathway.